Last reviewed · How we verify

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

NCT04539808 PHASE2 ACTIVE_NOT_RECRUITING Results posted

This phase II trial evaluates whether early switching from modified fluorouracil/irinotecan/leucovorin/oxaliplatin (mFOLFIRINOX) chemotherapy regimen to a combination of gemcitabine and nab-paclitaxel (GA) before surgery is effective in treating patients with pancreatic cancer that can be surgically removed (resectable or borderline resectable), or that has spread to nearby tissue or lymph nodes and cannot be removed by surgery (locally-advanced unresectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, oxaliplatin, gemcitabine, and nab-paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The study will also evaluate the drug losartan in combination with mFOLFIRINOX or GA.

Details

Lead sponsorOHSU Knight Cancer Institute
PhasePHASE2
StatusACTIVE_NOT_RECRUITING
Enrolment42
Start dateThu May 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
CompletionTue Jan 05 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Interventions

Countries

United States